Quantum BioPharma’s Imaging Study With Massachusetts General Hospital — The MRI-to-PET Moment For Multiple Sclerosis

Quantum BioPharma’s Imaging Study With Massachusetts General Hospital — The MRI-to-PET Moment For Multiple Sclerosis

From AGORACOM Small Cap CEO Interviews by AGORACOM

May 26, 2026 · 27 min

About this episode

Quantum BioPharma discusses its innovative imaging study with Massachusetts General Hospital and its lead drug candidate for multiple sclerosis.

When a company proves it can see what others couldn’t, the rules of drug development change overnight. Quantum BioPharma announced on May 18, 2026, that patient enrollment has reached the halfway mark in its collaborative imaging study with Massachusetts General Hospital, accompanied by encouraging preliminary results using a novel PET imaging technique capable of directly assessing demyelinated neurons with intact axons. The company’s lead drug candidate, Lucid-MS, targets the underlying mechanism of multiple sclerosis—demyelination—rather than merely suppressing the immune system like most existing therapies. With an IND application submitted to the FDA on April 1, 2026, Quantum BioPharma is positioned at the intersection of breakthrough imaging science and first-in-class therapeutics. WHAT YOU NEED TO KNOW Imaging Leap: PET scanning with [18F]3F4AP tracer provides up to 10x more accuracy than conventional MRI in measuring myelin damage and repair—potentially establishing a new FDA biomarker standard. Halfway Validated: First cohort successfully imaged at MGH showing robust signal in acute MS lesions; study completion expected within six months. First-in-Class: Lucid-MS targets…

Topics covered

Keywords

Mentioned in this episode

Organizations: Quantum BioPharma, Massachusetts General Hospital

Products: Lucid-MS

Places: United States, MS therapeutic market

More episodes of AGORACOM Small Cap CEO Interviews

Explore listener stats, chart rankings, contacts and more on the AGORACOM Small Cap CEO Interviews podcast page.